ADMA Biologics Q2 Earnings Preview: Expecting $0.14 EPS and $121.77M Revenue
PorAinvest
martes, 5 de agosto de 2025, 5:41 pm ET1 min de lectura
ADMA--
In its previous quarterly report, ADMA Biologics reported a 40.2% increase in revenue year-over-year but missed earnings expectations, reporting $0.14 EPS against an anticipated $0.16. The company's revenue for the quarter was $114.80 million, compared to the consensus estimate of $116.40 million. The company's net margin was 45.01%, and its return on equity was 47.16%.
Over the past 90 days, revenue estimates for ADMA Biologics have remained relatively stable, with the full year 2025 revenue estimate at $0.51 billion. Conversely, earnings estimates have declined from $0.71 per share to $0.61 per share for the full year 2025 [1].
ADMA Biologics operates as an end-to-end commercial biopharmaceutical company, manufacturing, marketing, and developing specialty biologics for the treatment of immunodeficient patients and others at risk for infectious diseases. The company's products include ASCENIV™, BIVIGAM®, and NABI-HB®, with SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia, in development.
The company's management team will host a live conference call and audio webcast on August 6th at 4:30 p.m. ET to discuss its financial results and other updates. Investors are encouraged to register for the call to receive the dial-in numbers and unique PIN [2].
References:
[1] https://www.gurufocus.com/news/3035133/adma-biologics-inc-adma-q2-2025-earnings-report-preview-what-to-look-for
[2] https://www.biospace.com/press-releases/adma-biologics-to-report-second-quarter-2025-financial-results-on-august-6-2025
ADMA Biologics is set to release Q2 2025 earnings on August 6th, with a consensus EPS estimate of $0.14 and revenue estimate of $121.77M (+13.6% Y/Y). Over the last 3 months, EPS estimates have seen a decline, while revenue estimates have remained relatively stable.
ADMA Biologics, Inc. (ADMA) is scheduled to release its second-quarter 2025 earnings on August 6th, with analysts expecting earnings of $0.14 per share and revenue of $121.77 million. The consensus estimate reflects a year-over-year growth rate of 13.6% in revenue, while earnings per share (EPS) estimates have seen a decline over the past three months.In its previous quarterly report, ADMA Biologics reported a 40.2% increase in revenue year-over-year but missed earnings expectations, reporting $0.14 EPS against an anticipated $0.16. The company's revenue for the quarter was $114.80 million, compared to the consensus estimate of $116.40 million. The company's net margin was 45.01%, and its return on equity was 47.16%.
Over the past 90 days, revenue estimates for ADMA Biologics have remained relatively stable, with the full year 2025 revenue estimate at $0.51 billion. Conversely, earnings estimates have declined from $0.71 per share to $0.61 per share for the full year 2025 [1].
ADMA Biologics operates as an end-to-end commercial biopharmaceutical company, manufacturing, marketing, and developing specialty biologics for the treatment of immunodeficient patients and others at risk for infectious diseases. The company's products include ASCENIV™, BIVIGAM®, and NABI-HB®, with SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia, in development.
The company's management team will host a live conference call and audio webcast on August 6th at 4:30 p.m. ET to discuss its financial results and other updates. Investors are encouraged to register for the call to receive the dial-in numbers and unique PIN [2].
References:
[1] https://www.gurufocus.com/news/3035133/adma-biologics-inc-adma-q2-2025-earnings-report-preview-what-to-look-for
[2] https://www.biospace.com/press-releases/adma-biologics-to-report-second-quarter-2025-financial-results-on-august-6-2025

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios